Champions Oncology reported total revenue of $15 million for its second quarter of fiscal 2026, a 11% year‑over‑year increase driven by stronger demand for its core oncology services and a new data‑licensing stream. The company’s oncology‑services segment generated $7.8 million in profit, reflecting a 52% margin that expanded from 45% in the same quarter a year earlier, thanks to flat cost of sales and operational efficiencies.
Net income for the quarter was $237,000, a modest but solid figure that beat consensus estimates. Adjusted EBITDA reached $843,000, up from roughly $800,000 in the prior quarter, indicating that the company is maintaining profitability while investing in growth initiatives.
First‑half fiscal 2026 highlights show total revenue of $29 million, a 5% year‑over‑year gain, and oncology‑services profit of $13.8 million with a 47% margin. Adjusted EBITDA for the six‑month period was $962,000, underscoring steady growth as the data platform and radiopharmaceutical capabilities expand.
CEO Robert Brainin said the results “reinforced our confidence in the Company’s ongoing return to growth” and that the firm remains “on track to deliver year‑on‑year revenue growth and to achieve positive adjusted EBITDA for the full fiscal year.” CFO David Miller noted that the 11% revenue rise was driven by improved conversion of booked work and fewer cancellations, while flat cost of sales helped lift gross margin to 52%.
Management reiterated its guidance for the remainder of the year, emphasizing disciplined cost control and targeted investment in the data platform. The company’s outlook signals confidence that the data‑licensing and radiopharmaceutical streams will continue to contribute to long‑term growth while maintaining profitability in the core services business.
The market reacted positively, with shares rising in after‑hours trading. Investors highlighted the revenue beat and margin expansion as key drivers of the favorable response, reflecting confidence in Champions Oncology’s execution and future growth prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.